Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Deinove SAS.

    Client Virtual Booth

    DEINOVE SAS

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Deinove SAS
    France Flag
    Country
    Country
    France
    Address
    Address
    ZAC Euromédecine II, Cap Sigma, 1682 Rue de la Valsière, 34790 Grabels
    Telephone
    Telephone
    +33 (0)4 48 19 01 00
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.deinove.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/deinove
    Twitter
    Twitter
    https://twitter.com/Deinove

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    DEINOVE To Present Data On DNV3837 At The ESCMID/ASM Conference in Dublin

    Details:

    DNV3837, a prodrug of the DNV3681 molecule (also known as MCB3681) is a narrow-spectrum, hybrid oxazolidinone-quinolone synthetic antibiotic targeting only Gram-positive bacteria. It is developed as a highly active first-line treatment targeting C. diff.


    Lead Product(s): Oxaquin

    Therapeutic Area: Infections and Infectious Diseases Product Name: DNV3837

    Highest Development Status: Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable October 05, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    The Second Part of the Phase II Clinical Trial of DNV3837 in Clostridioides Difficile Infections to Be Extended to Canada

    Details:

    DNV3837 is a novel 2-in-1 small molecule that combines a quinolonyl group with an oxazolidinone moiety and is converted, in vivo, is currently being evaluated for the treatment of life-threatening Clostridioides difficile severe gastrointestinal infections.


    Lead Product(s): Oxaquin

    Therapeutic Area: Infections and Infectious Diseases Product Name: DNV3837

    Highest Development Status: Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 07, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    DNV3837 Antibiotic Candidate: the Phase II Trial Continues in the US

    Details:

    DNV3837 targets the treatment of Clostridioides difficile gastrointestinal infections (CDI), a pathogen classified as urgent threat by the U.S. Centers for Disease Control and Prevention (CDC).


    Lead Product(s): Oxaquin

    Therapeutic Area: Infections and Infectious Diseases Product Name: DNV3837

    Highest Development Status: Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable July 15, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Enrolment of first patient in Phase II trial testing DNV3837 in Clostridioides difficile infections

    Details:

    The Phase II clinical trial aims to evaluate the efficacy, safety and pharmacokinetics of DNV3837 in patients with Clostridioides difficile gastrointestinal infection (CDI).


    Lead Product(s): Oxaquin

    Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

    Highest Development Status: Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable January 27, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search